ELETRIPTAN HYDROBROMIDE (eletriptan hydrobromide) by Viatris (2) is 5-ht 1b , 5-ht 1d and 5-ht 1f receptors, has modest affinity for 5-ht 1a , 5-ht 1e , 5-ht 2b and 5-ht 7 receptors. Approved for cluster headache (), migraine, any subsequent attacks. First approved in 2017.
Drug data last refreshed 21h ago
5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide)…
Worked on ELETRIPTAN HYDROBROMIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.